The latest coronavirus developments and scientific research on prevention and treatment.
Although most patients diagnosed with Covid-19 will quickly recover, some people experience symptoms that linger well after they start testing negative again — including insomnia. Scientists already knew… read more.
The NHS must treat at least 10 per cent more non-emergency hospital cases a month if it is to successfully start reducing the hefty backlog caused by the… read more.
From virtual dance parties and raves to virtual happy hours and potlucks – online gatherings reached new heights during COVID-19, helping individuals stay connected during lockdowns. While it’s… read more.
An unprecedented resurgence in invasive meningococcal disease followed the lifting of pandemic restrictions in France, according to a paper published in the Journal of Infection and Public Health… read more.
Since the COVID-19 pandemic began, extensive research has emerged detailing the virus’s ability to attack multiple organ systems, potentially resulting in a set of enduring and often disabling… read more.
A new study published today in the American Journal of Infection Control (AJIC), based on a survey of healthcare professionals conducted during the height of the COVID-19 pandemic, suggests that new efforts… read more.
More older Americans use cannabis now than before the pandemic, with 12% saying they’ve consumed a THC-containing substance in the past year and 4% saying they do so… read more.
Junshi Biosciences has revealed the final results for its Covid-19 pill VV 116 (mindeudesivir hydrobromide), indicating its efficacy. The data, which was published in The Lancet Infectious Diseases… read more.
Covid-19 vaccination prior to infection significantly reduces the risk of developing post-covid-condition (PCC), commonly known as long covid, researchers reported on Nov. 22, 2023 in The BMJ/British Medical… read more.
Researchers from a study of patients treated for acute COVID-19 report that virologic rebound takes place in about 20.8 percent of subjects treated with nirmatrelvir-ritonavir (N-R, Paxlovid) versus… read more.
In an analysis of published prospective studies of people of all ages with confirmed SARS-CoV-2 infection who were followed for at least 12 months, pre-existing allergic conditions were… read more.
Despite the Centers for Disease Control and Prevention warning this year will be potentially dangerous for respiratory illnesses, a third of Americans are not concerned about the threat,… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
